MDMAT

MDMAT (6,7-methylenedioxy-N-methyl-2-aminotetralin) is a selective serotonin releasing agent (SSRA) and entactogen drug. It is the N-methylated derivative of MDAT, similarly to the relationship of MDMA to MDA.^[2][3] It has been theorized to have less long-term neurotoxicity and less hallucinogenic effects than other MDxx derivatives,^[4] but no formal scientific research has been conducted specifically on MDMAT.

MDMAT

Clinical data
ATC code	none
Legal status
Legal status	US: Uncontrolled;[1] May fall under the Federal Analogue Act
Identifiers
IUPAC name N-Methyl-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine
CAS Number	34620-52-5 Y
PubChem CID	23324601
ChemSpider	14921388 N
UNII	JV4FSP6YL3
CompTox Dashboard (EPA)	DTXSID80632929
Chemical and physical data
Formula	C12H15NO2
Molar mass	205.257 g·mol−1
3D model (JSmol)	Interactive image
SMILES C3c1cc2OCOc2cc1CCC3NC
InChI InChI=1S/C12H15NO2/c1-13-10-3-2-8-5-11-12(15-7-14-11)6-9(8)4-10/h5-6,10,13H,2-4,7H2,1H3 N Key:MTRLJTZQUZHTJI-UHFFFAOYSA-N N
NY (what is this?)  (verify)

There is a lack of research on MDMAT in general, with much of the research and citation in literature being in reference to the wider pharmalogical/chemical class as a whole.

Chemistry

MDMAT is a substituted methylenedioxyphenethylamine, having structural similarities to MDMA and MDA.

See also

• 2-Aminotetralin
• Substituted methylenedioxyphenethylamine